ZUG, Switzerland - Wednesday, 11. February 2026
Restylane® Refyne™ and Restylane Defyne™ are the first Optimal Balance
Technology (OBT™) hyaluronic acid injectables ever approved and launched
in Japan, bringing advanced flexibility and natural movement to the
market1,2
This expands Galderma’s Restylane portfolio in Japan to
four products, enabling treatment of a wider spectrum of patient and
practitioner needs3,4
These two new launches underscore Galderma’s accelerating growth across the Japan & Asia Pacific (JPAC) region
(BUSINESS
WIRE)--Galderma (SIX: GALD), the pure-play dermatology category leader,
has announced the launch of Restylane Defyne and Restylane Refyne: the
first OBT‑based hyaluronic acid injectables ever authorized in Japan.1,2
The products – designed for injection into the mid-to-deep dermis for
the correction of moderate to severe facial wrinkles and folds – are now
commercially available in the market.1,2
Restylane Defyne and
Refyne leverage the unique balance of softness, flexibility, and support
delivered by Galderma’s proprietary OBT – designed to move in harmony
with facial expressions while maintaining shape and lift – and are the
first and only hyaluronic acid injectables clinically proven to restore
youthful facial expressions.1,2,5-11 Restylane Refyne offers a smooth,
flexible gel, ideal for delicate, highly expressive areas, while
Restylane Defyne provides support for areas such as the jawline and
deeper facial folds.1,2,5-11 These launches mark a major milestone for
Galderma and represent an important chapter in its JPAC growth strategy,
supporting the company’s continuing expansion in one of the region’s
most dynamic aesthetics markets.
“The introduction of
OBT technology to Japan is a significant milestone not only for
clinicians but for the region’s aesthetic landscape as a whole. By
combining the power of both NASHA® and OBT within the Restylane
portfolio in Japan, physicians can tailor treatments more precisely than
ever before. This broader set of tools supports natural‑looking,
expressive outcomes and aligns Japan with international best practice.”
DR. STEPHANIE LAM
PLASTIC SURGEON, CENTRAL HEALTH MEDICAL PRACTICE
HONG KONG
The
Restylane portfolio in Japan now includes four products in total, with
Refyne and Defyne joining NASHA-powered products, Restylane Classyc™ and
Restylane Lyft™.1-4 This versatile range enables clinicians to meet
diverse patient needs, from soft, flexible formulations that smooth fine
lines, to firmer gels that deliver contouring and support.1-7,12,13
The
approvals of Restylane Refyne and Defyne in Japan were based on two
pivotal, double-blinded, randomized, active-controlled phase III studies
investigating the products in 171 and 162 subjects, respectively.
Restylane Refyne and Defyne met the studies’ endpoints, demonstrating a
clinically meaningful improvement in wrinkle severity for up to 12
months, with most patients reporting at least a 1-grade improvement in
self-assessment scores after six weeks.1,2
“The approval
of Restylane Defyne and Refyne – the first OBT HA injectables ever
authorized in Japan – is a landmark moment for Galderma in the region. A
decade after NASHA’s introduction to this market, we are proud to now
offer a fully rounded Restylane portfolio that gives healthcare
professionals even more precision and flexibility to meet the needs of
their patients. Japan is an important growth engine for our business,
and this milestone underscores our long-term commitment to bringing
world-leading aesthetic technologies to the region.”
HON KEONG CHOO
HEAD OF JPAC REGION
GALDERMA
With
over 30 years of innovation and more than 77 million treatments
administered worldwide, Restylane is highly relevant in addressing some
of today’s most significant aesthetic trends and needs, from improving
facial harmony following medication-driven weight loss to growing
concerns around menopause-related skin health and aging.5,14-17 The
arrival of OBT technology in Japan now aligns the market more closely
with global Restylane availability, reinforcing the brand’s position as
the world’s most scientifically studied and diverse hyaluronic acid
injectables range.
About the Restylane portfolio
Restylane
hyaluronic acid treatments are designed differently to go beyond
volumizing for natural-looking results.4,5,18,19 Our hyaluronic acid is
minimally modified and our innovative manufacturing process preserves
its biocompatibility while creating individual products designed for a
specific purpose.20-22 Powered by NASHA, NASHA HD™, OBT and SB-NASHA™
technologies, Restylane offers gels with the highest firmness to the
highest flexibility, enabling personalized treatments that deliver
structural support, natural-looking results, and a healthy
glow.12,13,23,24 Trusted for almost three decades, our hyaluronic acid
gels work in sync with your skin for 100% natural-looking results.5-7
About Galderma
Galderma
(SIX: GALD) is the pure-play dermatology category leader, present in
approximately 90 countries. We deliver an innovative, science-based
portfolio of premium flagship brands and services that span the full
spectrum of the fast-growing dermatology market through Injectable
Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since
our foundation in 1981, we have dedicated our focus and passion to the
human body’s largest organ – the skin – meeting individual consumer and
patient needs with superior outcomes in partnership with healthcare
professionals. Because we understand that the skin we are in shapes our
lives, we are advancing dermatology for every skin story. For more
information: www.galderma.com.
References
Restylane® Defyne™. IFU. Japan. Available online. Accessed February 2026
Restylane® Refyne™. IFU. Japan. Available online. Accessed February 2026
Restylane® Lyft™. IFU. Japan. Available online. Accessed February 2026
Restylane® Classyc™. IFU. Japan. Available online. Accessed February 2026
Di Gregorio C, et al. 25+ years of experience with the Restylane
portfolio of injectable HA fillers for facial aesthetic treatment.
E-poster presented at AMWC; March 27-29, 2024; Monaco
Solish N,
et al. Dynamics of HA fillers formulated to maintain natural facial
expression. J Cosmet Dermatol. 2019;18(3):738-746. doi:
10.1111/jocd.12961
Philipp‐Dormston WG, et al. Perceived
naturalness of facial expression after HA filler injection in nasolabial
folds and lower face. J Cosmet Dermatol. 2020;19(7):1600-1606. doi:
10.1111/jocd.13205
Philipp‐Dormston WG, et al. Evaluating
perceived naturalness of facial expression after fillers to the
nasolabial folds and lower face with standardized video and photography.
Dermatol Surg. 2018;44(6):826-832. doi: 10.1097/DSS.0000000000001419.
Galderma. Data on file. MA-43049. xStrain and G’ Global HA filler rheology data. 2023
Galderma. Data on file. MA-42769. Restylane Defyne Clinical study report. 2020
Öhrlund Å. Evaluation of rheometry amplitude sweep cross-over point
as an index of flexibility for HA fillers. JCDSA. 2018;8(2):47-54
Galderma Data on file. MA-56724. X-strain and G’ including Shaype
Öhrlund Å. Differentiation of NASHA and OBT hyaluronic acid gels
according to strength, flexibility, and associated clinical
significance. J Drugs Dermatol. 2014;23(1):1332-1336. doi:
10.36849/JDD.7648
Galderma. Data on file. MA-57232 [Updated]. 77 Million treated. 2025
Galderma. Data on file. MA-55607. Restylane® 27 years data publications analysis. 2023
Fabi G, et al. The potential role of biostimulators/dermal fillers to
address menopause-related skin conditions. Poster presented at IMCAS;
January 29-31, 2026; Paris, France
Lorenc ZP, et al. Synergistic
efficacy and safety of poly-L-lactic acid biostimulator and hyaluronic
acid filler for facial fullness post weight loss due to glucagon-like
peptide-1 receptor agonist medication. Presented at the ASDS 2025 Annual
Meeting; November 13-16; Chicago, United States
Nikolis A, et
al. The role of clinical examination in midface volume correction using
hyaluronic acid fillers: should patients be stratified by skin
thickness? Aesthet Surg J Open Forum. 2020;2(1):1–12. doi:
10.1093/asjof/ojaa005
Talarico S, et al. High patient
satisfaction of a HA filler producing enduring full-facial volume
restoration: an 18- month open multicenter study. Dermatol Surg.
2015;41:1361–1369. doi: 10.1097/DSS.0000000000000549
Edsman K, et
al. Gel properties of hyaluronic acid dermal fillers. Dermatol Surg.
2012;38:1170–1179. doi: 10.1111/j.1524-4725.2012.02472.x.
Galderma. Data on file. MA-58650. Degree of modification of HA fillers.
Seo K. Facial volumization with fillers. Springer. 2021;29–83. doi: 10.1007/978-981-33-6212-3_2
Nikolis A, et al. Effectiveness and safety of a new hyaluronic acid
injectable for augmentation and correction of chin retrusion. J Drugs
Dermatol. 2024;23(4):255–261. doi: 10.36849/JDD.8145
Belmontesi M
et al. Injectable non-animal stabilized hyaluronic acid as a skin
quality booster: an expert panel consensus. J Drugs Dermatol.
2018;17(1):83–88.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260210555523/en/
Permalink
https://www.aetoswire.com/en/news/1102202653182
Contacts
For further information:
Christian Marcoux, M.Sc.
Chief Communications Officer
christian.marcoux@galderma.com
+41 76 315 26 50
Richard Harbinson
Corporate Communications Director
richard.harbinson@galderma.com
+41 76 210 60 62
Céline Buguet
Franchises and R&D Communications Director
celine.buguet@galderma.com
+41 76 249 90 87
Emil Ivanov
Head of Strategy, Investor Relations, and ESG
emil.ivanov@galderma.com
+41 21 642 78 12
Jessica Cohen
Investor Relations and Strategy Director
jessica.cohen@galderma.com
+41 21 642 76 43
